Результаты поиска

More Than an Adipokine: The Complex Roles of Chemerin Signaling in Cancer.

Chemerin is widely recognized as an adipokine, with diverse biological roles in cellular differentiation and metabolism, as well as a leukocyte chemoattractant. Research investigating the role of chemerin in the obesity-cancer relationship has provided evidence both for pro- and anti-cancer effects. The tumor-promoting effects of chemerin primarily involve direct effects on migration, invasion, and metastasis as well as growth and proliferation of cancer cells. Chemerin can also promote tumor growth via the recruitment of tumor-supporting mesenchymal stromal cells and stimulation of angiogenes

Совпадение в полном тексте источника
… Tummler et al. [ 118 ] reported that expression of chemerin 1 , but not chemerin 2 , was elevated (versus neural crest and benign neurofibroma cells) in tumors from patients with neuroblastoma, a pediatric cancer of the peripheral nervous system. …

Четвертое Международное совещание ИСЕВ, ISEV2015.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Current and Emerging Therapies for Targeting the ERK1/2 & PI3K Pathways in Cancer.

The ERK1/2 and PI3K signaling pathways play important roles in cellular proliferation, survival, differentiation, and metabolism. In cancer, these pathways are frequently dysregulated and overactivated, resulting in poor patient prognosis and resistance to treatment. These pathways are activated by receptor tyrosine kinases and send downstream signals to effectors such as RAS, RAF, MEK, AKT, and mTOR. In this review, we highlight the key components of the ERK1/2 and PI3K pathways, the roles they play in tumor progression, and the development of inhibitors and combination therapies designed to

Совпадение в полном тексте источника
… FDA-approved | FGFR-altered urothelial carcinoma RAS | Salirasib | RAS membrane disruptor | Phase II | KRAS-mutant solid tumors RAF + MEK | Dabrafenib + Trametinib | BRAF inhibitor + MEK inhibitor | FDA-approved combo | BRAF V600E/K melanoma MEK | Selumetinib | MEK1/2 inhibitor | FDA-approved | NF-1 plexiform neurofibroma …

Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway.

Transforming growth factor-beta (TGF-β) signaling regulates a wide range of biological processes. TGF-β plays an important role in tumorigenesis and contributes to the hallmarks of cancer, including tumor proliferation, invasion and metastasis, inflammation, angiogenesis, and escape of immune surveillance. There are several pharmacological approaches to block TGF-β signaling, such as monoclonal antibodies, vaccines, antisense oligonucleotides, and small molecule inhibitors. Galunisertib (LY2157299 monohydrate) is an oral small molecule inhibitor of the TGF-β receptor I kinase that specifically

Совпадение в полном тексте источника
… NCT00676507 TGF-β synthesis | Pirfenidone Etuary F-647 Esbriet ® Pirespa ® | III Approved for ideopathic pulmonary fibrosis in Europe, Canada, and Japan | Idiopathic pulmonary fibrosis, pulmonary fibrosis, focal glomerulosclerosis, diabetic nephropathy, neurofibromatosis type I and progressive plexiform neurofibromas …

Inhibition of Cxcr4 chemokine receptor signaling improves habituation learning in a zebrafish model of neurofibromatosis.

Neurofibromatosis type 1 (NF1) is a neurogenetic disorder caused by loss-of-function mutations in the gene neurofibromin 1 (NF1). NF1 encodes neurofibromin, a multifunctional tumor-suppressing protein that regulates Ras, cAMP and dopamine signaling. NF1 predisposes patients to a wide range of symptoms, including peripheral nerve tumors, brain tumors and cognitive dysfunction. Despite considerable work using animal models to investigate the role of neurofibromin in behavior, translating research into treatment for NF1-associated cognitive dysfunction has not yet been successful. Here, we provid…

Oncogenic influences of neurotrophin receptors: Shedding light on Trk biology.

During critical stages of neurodevelopment, tropomyosin receptor kinase receptors, encoded by NTRK genes, exhibit temporally driven differential peaks of expression to properly guide the establishment of the peripheral and central nervous systems. In addition, these neuronal systems exhibit non-canonical regulation of surrounding tissues, impacting organogenesis, homeostasis, plasticity, and regeneration. The same processes that guide neurodevelopment, such as differentiation, plasticity, and neuronal survival, are also hijacked in cancer, making the NTRK family an ideal candidate to study. Th

Совпадение в полном тексте источника
… THE ROLE OF TRK RECEPTOR SIGNALING IN NON-NERVOUS SYSTEM CANCERS The case for a mechanistic classification of non-neural cancers Trk receptor signaling in the PNS has been studied primarily through tumors that originate directly from neural or nerve-derived structures, such as schwannomas, neurofibromas …

Strategies to overcome the main challenges of the use of CRISPR/Cas9 as a replacement for cancer therapy.

CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats-associated protein 9) shows the opportunity to treat a diverse array of untreated various genetic and complicated disorders. Therapeutic genome editing processes that target disease-causing genes or mutant genes have been greatly accelerated in recent years as a consequence of improvements in sequence-specific nuclease technology. However, the therapeutic promise of genome editing has yet to be explored entirely, many challenges persist that increase the risk of further mutations. Here, we highlighted the main challenges fa

Совпадение в полном тексте источника
… Humanized neurofibroma model from induced pluripotent stem cells delineates tumor pathogenesis and developmental origins. J Clin Investig. 2021;131(1):e139807. doi: 10.1172/JCI139807. 46. Liu Y, Chen Y, Huang S, Ma X, Huang X, Wang X, et al. …

Molecular targeted therapy for anticancer treatment.

Since the initial clinical approval in the late 1990s and remarkable anticancer effects for certain types of cancer, molecular targeted therapy utilizing small molecule agents or therapeutic monoclonal antibodies acting as signal transduction inhibitors has served as a fundamental backbone in precision medicine for cancer treatment. These approaches are now used clinically as first-line therapy for various types of human cancers. Compared to conventional chemotherapy, targeted therapeutic agents have efficient anticancer effects with fewer side effects. However, the emergence of drug resistanc

Совпадение в полном тексте источника
… melanoma with BRAF mutations in combination with encorafenib (2018) | | RTK reactivation PI3K/STAT3 activation | Rash, diarrhea, fatigue, arthralgia | 157 , 167 , 168 , 239 – 241 MEK | Selumetinib (AZD6244, ARRY-142886) | Koselugo (Array Biopharma/ AstraZeneca) | Neurofibromatosis type 1 plexiform neurofibroma …

СРП 2013

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… Cholangiocarcinoma Associated With a Benign Cystic anomaly in an Adolescent CR-036 | Rotaru | Unusual Presentation of a Rare Case of Extramedullary Hematopoiesis Involving the Sino-Nasal Tract in an African American Patient With Sickle Cell Anemia CR-037 | Zammerilla | Histopathologic Diagnosis of Neurofibroma …

Neuroscience in peripheral cancers: tumors hijacking nerves and neuroimmune crosstalk.

Cancer neuroscience is an emerging field that investigates the intricate relationship between the nervous system and cancer, gaining increasing recognition for its importance. The central nervous system governs the development of the nervous system and directly affects brain tumors, and the peripheral nervous system (PNS) shapes the tumor microenvironment (TME) of peripheral tumors. Both systems are crucial in cancer initiation and progression, with recent studies revealing a more intricate role of the PNS within the TME. Tumors not only invade nerves but also persuade them through remodeling

A Holistic Review of Oncological Drug Targets and Trajectories of Resistance in Cancer Therapy.

The prolonged and intricate history of oncological treatments has transitioned significantly since the introduction of chemotherapy. Substantial therapeutic benefits in cancer therapy have been achieved by the integration of conventional treatments with molecular biosciences and omics technologies. Human epidermal growth factor receptor, hormone receptors, and angiogenesis factors are among the established therapies in tumor reduction and managing side effects. Novel targeted therapies like KRAS G12C, Claudin-18 isoform 2 (CLDN18.2), Trophoblast cell-surface antigen 2 (TROP2), and epigenetic r

Совпадение в полном тексте источника
… . | Selumetinib | KOSELUGO | 9/10/2025 | MEK inhibitor | Selectively inhibits MEK1/2, blocking the RAS-RAF-MEK-ERK signaling pathway | RAS-RAF-MEK-ERK pathway | SPRINT Phase II Stratum I study and the SPRINKLE study | Pediatric neurofibromatosis type 1 (NF1) with symptomatic, inoperable plexiform neurofibromas …

Diseases of the Nervous System

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Электронные постеры

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Targeting MDM2, RAS, and PCNA for cancer targeted therapy: pan-cancer approaches vs. cancer-specific strategies.

Cancer therapy and cancer drug discovery and development have been historically focused on specific cancers (tissue/organ of origin). However, with advances in molecular biology and multi-omics of cancer, there is a trend to develop pan-cancer therapeutic modalities. In targeted therapy, pan-cancer strategies target common molecular alterations across different cancer types and specific cancer strategies are tailored to the unique biological characteristics of individual tumor types. Each approach offers distinct advantages and limitations, and understanding these differences is critical in th

From post-war reconstruction to the twenty-first century - ophthalmic pathology in Freiburg 1945-2015. Part 2: review of 43,169 histological diagnoses from 39,256 specimens collected over 71 years at a large German tertiary eye care centre.

BACKGROUND: Ophthalmic pathology is essential for diagnosing ocular diseases, correlating clinical and histopathological findings, and advancing research. The Eye Center at the University of Freiburg, Germany, has archived histopathological specimens since 1945, offering a unique resource to analyse long-term diagnostic trends. This study examines 43,169 diagnoses from 39,256 specimens over 71 years (1945–2015), providing insights into the evolution of ophthalmic pathology at a major tertiary care centre. METHODS: We performed a retrospective analysis of all archived ophthalmic pathology repor

Совпадение в полном тексте источника
… 2.0%) | Epidermal cyst | 120 (2.4%) | Xanthelasma | 305 (2.9%) | Dermoid cyst | 2 (2.4%) | Actinic keratosis | 6 (2.9%) | Granuloma | 13 (1.7%) | Hemangioma | 34 (1.5%) | Granuloma | 56 (1.9%) | Dermoid cyst | 80 (1.6%) | Epidermal cyst | 299 (2.8%) | Fibroma | 2 (2.4%) | Dermoid cyst | 5 (2.4%) | Neurofibroma …

Childhood Cancer: Occurrence, Treatment and Risk of Second Primary Malignancies.

Cancer represents the leading cause of disease-related death and treatment-associated morbidity in children with an increasing trend in recent decades worldwide. Nevertheless, the 5-year survival of childhood cancer patients has been raised impressively to more than 80% during the past decades, primarily attributed to improved diagnostic technologies and multiagent cytotoxic regimens. This strong benefit of more efficient tumor control and prolonged survival is compromised by an increased risk of adverse and fatal late sequelae. Long-term survivors of pediatric tumors are at the utmost risk fo

Совпадение в полном тексте источника
… Mutations in NF1 can cause neurofibromas (NF), low- and high-grade gliomas (L/HGGs), and malignant peripheral nerve sheath tumors. Mutations in DICER1 are related to proneness to pleuropulmonary blastoma, kidney tumors, CNS tumors, and embryonal rhabdomyosarcoma (RMS) [ 91 ]. …

Электронные постеры

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Устные бесплатные бумажные сессии.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

The Proceedings of the 19th International Cancer Imaging Society Meeting and Annual Teaching Course : Verona, Italy. 7 - 9 October 2019.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… Isaac R Francis University of Michigan (Michigan Medicine), Ann Arbor, Michigan, USA NEOPLASMS: Soft tissue masses: Sarcomas, lymphoma, lymph node metastases and extra gonadal germ cell tumours Myxoid masses: (mixed soft tissue and low density) Neurogenic: Schwannoma, neurilemoma, ganglioneuroma, neurofibroma …

Резюме: 32 Второй Конгресс ЭСП и Международный конгресс XXXIII МПД.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.